Biosimilars

Insight and thought leadership from our biosimilar experts

The future of oncology biosimilars: Considerations for development through 2040

As patents for over 100 biologics—mainly in oncology—expire, biosimilars have a growing opportunity to expand access and enter established and underserved markets. This whitepaper explores the evolving oncology biosimilars landscape, regulatory strategies, challenges to market access, and innovations in post-market monitoring.

Read the whitepaper
SVG Image
biosimilars and oncology

ICON's Centre for Biosimilar Drug Development

Learn more about how ICON's cross function service offering can support your biosimilar drug development projects.